Dr. Kastellorizios’ research focuses on drug delivery technologies including translational and personalized nanomedicine, regulatory science, formulation development, and medical devices.
Translational Research: We are developing novel anticancer nanoparticle characterization methods designed to bridge preclinical and clinical testing. We utilize solid tumor biopsies from cancer patients and test them against existing as well as novel nanomedicine formulations. Our long term goal is to accelerate the discovery of novel anticancer therapies and reduce the associated drug development costs.
Personalized medicine and Health Disparities: we are developing a diagnostic for personalized treatment of metastatic breast cancer, and we are studying its application on breast cancer health disparities in African American women as they apply to nanotherapy outcomes. Our goal is to be able to make sure that each patient or patient group receives the therapy that has the highest chance of success in their particular case.
Regulatory Science: development of novel quality assurance testing methods for nanoparticle drug products. We apply the principles of Physical Pharmacy and Physical Chemistry to characterize nanoparticle formulations based on their unique interfacial properties. This method will assist in nanomedicine manufacturing in order to reduce drug costs.
Formulation Development and Medical Devices: in collaboration with other researchers that work on new drug candidates, generic drug formulations, and medical devices. These smaller projects are utilized to train Dr. Kastellorizios’ lab members in the science and application of Pharmaceutical Technology.
Translational Research: We are developing novel anticancer nanoparticle characterization methods designed to bridge preclinical and clinical testing. We utilize solid tumor biopsies from cancer patients and test them against existing as well as novel nanomedicine formulations. Our long term goal is to accelerate the discovery of novel anticancer therapies and reduce the associated drug development costs.
Personalized medicine and Health Disparities: we are developing a diagnostic for personalized treatment of metastatic breast cancer, and we are studying its application on breast cancer health disparities in African American women as they apply to nanotherapy outcomes. Our goal is to be able to make sure that each patient or patient group receives the therapy that has the highest chance of success in their particular case.
Regulatory Science: development of novel quality assurance testing methods for nanoparticle drug products. We apply the principles of Physical Pharmacy and Physical Chemistry to characterize nanoparticle formulations based on their unique interfacial properties. This method will assist in nanomedicine manufacturing in order to reduce drug costs.
Formulation Development and Medical Devices: in collaboration with other researchers that work on new drug candidates, generic drug formulations, and medical devices. These smaller projects are utilized to train Dr. Kastellorizios’ lab members in the science and application of Pharmaceutical Technology.